Real-world Daptomycin Use in Chinese ICUs

Real-world Effectiveness and Safety on Daptomycin in Gram-Positive Infections in Chinese Intensive Care Units

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03588637

Enrollment

200

Registered

2018-07-17

Start date

2018-06-01

Completion date

2021-12-30

Last updated

2022-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Daptomycin, Intensive Care Unit, Real-world Study

Brief summary

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.

Interventions

OTHERNo intervention

No intervention

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

1 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Patient who received at least one dose of daptomycin

Exclusion criteria

* No

Design outcomes

Primary

Measure	Time frame	Description
mortality	30 days	death
Cure Rate	30 days	clinical and microbiological effectiveness

Secondary

Measure	Time frame	Description
Number of participants with treatment-related adverse events	30 days	organ dysfunction，allergy，creatine kinase levels，eosinophilic pneumonia，etc.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026